NCM · Financial Statements
Virax Biolabs Group Limited (VRAX) Financial Statements
$1.87
NCM: VRAX
Market Cap $348989
Overview Financials Dividend Virax Biolabs Group Limited most recently reported annual revenue of $0, net profit of $-5.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2022 2023 2024 2025 2026 Revenue $0 $0 $0 $0 $0 Operating Profit $-2.0M $-6.0M $-6.0M $-6.0M $-6.0M Net Profit $-2.0M $-5.0M $-7.0M $-6.0M $-5.0M EPS $-37.50 $-128.25 $-84.00 $-48.75 $-12.64 Op Margin — -66963.7% -4153.3% -97344.8% -51515.2%
Balance Sheet (USD)
Metric 2022 2023 2024 2025 2026 Total Assets $0 $10.0M $5.0M $6.0M $8.0M Total Liabilities $1.0M $1.0M $0 $1.0M $1.0M Cash $0 $9.0M $4.0M $4.0M $6.0M Borrowings $0 $0 $0 $0 $0
Cash Flow (USD)
Metric 2022 2023 2024 2025 2026 Operating Cash Flow $-1.0M $-4.0M $-6.0M $-5.0M $-5.0M Investing Cash Flow $0 $-1.0M $-2.0M $-1.0M $-1.0M Financing Cash Flow $0 $0 $2.0M $1.0M $4.0M Net Cash Flow $0 $9.0M $-6.0M $1.0M $2.0M Free Cash Flow $-1.0M $-4.0M $-7.0M $-5.0M $-5.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.00 EV / EBITDA 0.71 FCF Yield -1773.30% Quick Ratio 9.90 Interest Coverage -96.86 Return 1Y -84.14% Return 3Y -96.54% Return 5Y —
Screens featuring this stock